Download full-text PDF

Source

Publication Analysis

Top Keywords

[androgen excretion
4
excretion men
4
men angina
4
angina pectoris
4
pectoris cardialgia
4
cardialgia changes
4
changes lipoprotein
4
lipoprotein metabolism
4
metabolism blood
4
blood coagulation
4

Similar Publications

The detection of endogenous anabolic androgenic steroids (EAAS) is performed with the Steroidal Module of the Athlete Biological Passport (ABP). Glucocorticoids (GC) could be a confounding factor to the ABP Steroidal Module because they inhibit the hypothalamic-pituitary-adrenal axis, and ABP metabolites have partial adrenal origin. In previous studies, single-dose systemic GC administrations have been shown to reduce the urinary ratios A/T and 5αdiol/E.

View Article and Find Full Text PDF

Rationale: Stanozolol, an anabolic androgenic steroid listed in Part S1 of the World Anti-Doping Agency Prohibited List, exhibits a low response and significant matrix interference in urine samples when using liquid-liquid extraction-gas chromatography-mass spectrometry (GC-MS). Enhancing sample preparation techniques remains essential for the effective detection of stanozolol and its metabolites.

Methods: A method for determining stanozolol and its metabolites (3'-OH-stanozolol, 4β-OH-stanozolol, and 16β-OH-stanozolol) in human urine was developed and validated using GC-Orbitrap high-resolution MS combined with optimized mixed-mode solid-phase extraction (SPE).

View Article and Find Full Text PDF

Progressive 11β-Hydroxysteroid Dehydrogenase Type 2 Insufficiency as Kidney Function Declines.

J Clin Endocrinol Metab

September 2024

Center for Adrenal Disorders, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston MA, USA.

Background: It has been postulated that chronic kidney disease (CKD) is a state of relative 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) insufficiency, resulting in increased cortisol-mediated mineralocorticoid receptor (MR) activation. We hypothesized that relative 11βHSD2 insufficiency manifests across a wide spectrum of progressively declining kidney function, including within the normal range.

Methods: Adult participants were recruited at two academic centers.

View Article and Find Full Text PDF

Adolescent transgender medicine is a growing clinical field. Gender-affirming medications for transgender youth may include gonadotropin-releasing hormone (GnRH) agonists, gender-affirming hormones or both. To evaluate the potential effects of GnRH agonists (puberty suppression) on pharmacokinetic processes for transgender youth, we searched PubMed from inception to May 2024 for publications on the effects of GnRH agonists on drug absorption, distribution, metabolism or excretion for transgender adolescents or effects on hormones (including gonadotropins, adrenal androgens, sex steroids) that are associated with changes in drug metabolism during puberty in the general adolescent population.

View Article and Find Full Text PDF
Article Synopsis
  • - The study explores potential causes of gender dysphoria (GD), specifically investigating the impact of endocrine-disrupting chemicals (EDCs) like bisphenol A (BPA), thiamethoxam, and fipronil on hormone-naïve transmen compared to cis-women.
  • - Researchers found that drug-naïve transmen had higher levels of androgens (like testosterone) than cis-women, while thiamethoxam levels were higher in cis-women; BPA and fipronil levels were similar across both groups.
  • - The findings suggest that while EDCs may play a role in GD, they are not the sole factor, and the high testosterone levels in trans
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!